Trinity Biotech plc
TRIB
$0.763
$0.0557.77%
NASDAQ
| 06/30/2024 | 12/31/2023 | 09/30/2023 | 06/30/2023 | 09/30/2022 | |
|---|---|---|---|---|---|
| Net Income | -- | 41.43% | 11.18% | -40.55% | -308.36% |
| Total Depreciation and Amortization | -- | -22.54% | -3.48% | 20.19% | -34.30% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -- | -63.27% | -47.47% | -19.21% | 49.89% |
| Change in Net Operating Assets | -- | -118.24% | 44.56% | 89.41% | -288.38% |
| Cash from Operations | -- | -1,158.61% | -730.49% | -277.86% | -92.69% |
| Capital Expenditure | -- | 27.07% | 14.05% | -6.36% | -150.46% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | 41.20% | 52.80% | 53.94% | 49.93% |
| Cash from Investing | -- | 514.19% | 435.06% | 402.79% | 25.74% |
| Total Debt Issued | -- | -95.00% | -95.00% | -95.00% | 5,569.78% |
| Total Debt Repaid | -- | 90.03% | 90.00% | 89.92% | -3,934.90% |
| Issuance of Common Stock | -- | -- | -98.48% | -98.48% | -- |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | 36.78% | 43.77% | 38.09% | -433.43% |
| Cash from Financing | -- | -30.24% | -8.12% | -21.50% | -245.58% |
| Foreign Exchange rate Adjustments | -- | 62.39% | 764.71% | -209.52% | 115.32% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -- | 85.07% | 95.09% | 120.78% | -367.26% |